Director at $PTGX sells 4,000 Shares in Insider Sale

William D. Waddill, a director at $PTGX, recently sold 4,000 shares of the company, which amounted to approximately $237,000. This transaction represented about 30.5% of his holdings of this particular class of stock, leaving him with 9,130 shares of $PTGX stock. The data on this sale was obtained from a recent SEC filing.

In the past six months, $PTGX insiders have engaged in trading the company’s stock on the open market on 11 occasions. These trades consisted of 11 sales and no purchases. Notable transactions include Dinesh V Ph.D. Patel, the President and CEO, selling 62,859 shares valued at $3,450,577, Arturo MD Molina, the Chief Medical Officer, selling 50,514 shares valued at $2,826,250, and Asif Ali, the Chief Financial Officer, selling 26,659 shares valued at $1,543,329. William D. Waddill has conducted two sales, including the recent 4,000 share sale.

Regarding hedge fund activity, institutional investors have made significant moves with $PTGX stock. UBS GROUP AG added an impressive 2,148,380 shares to their portfolio in the second quarter of 2025, worth an estimated $118,740,962. On the other hand, PACER ADVISORS, INC. removed 1,876,466 shares from their portfolio in the first quarter of 2025. Other notable additions include ADAGE CAPITAL PARTNERS GP, L.L.C., BVF INC/IL, HOLOCENE ADVISORS, LP, DRIEHAUS CAPITAL MANAGEMENT LLC, and STATE STREET CORP.

Analysts have been actively following $PTGX, issuing buy ratings from 8 firms and no sells in recent times. JMP Securities issued a “Market Outperform” rating, while Citigroup, HC Wainwright & Co., Wedbush, Truist Securities, BMO Capital, and Citizens Capital Markets all issued buy or outperform ratings. Price targets set by analysts have a median of $71.0, with varying targets from analysts such as Jonathan Wolleben, Geoff Meacham, Douglas Tsao, Yun Zhong, Srikripa Devarakonda, and Etzer Darout.

It is important to note that this article provides information on insider transactions, hedge fund activities, analyst ratings, and price targets related to $PTGX and does not constitute financial advice. Readers should refer to Quiver Quantitative’s disclaimers for more information.